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Since the metaanalysis conducted by Pignon et al, chest radiotherapy 
is now a classical component in the treatment of limited small cell lung 
cancer. The next question is to deﬁne the optimal way of combining 
drugs and radiation including the drugs, the sequence and the 
characteristics of the radiation treatment (doses, volumes, fractionation 
and timing). So, the issue of timing is only one variable amongst 
different possibilities. This issue have been addressed by a series of 
randomised trials and metaanalysis. 
Six randomised trials have addressed the question of the timing: 5 
have used a concurrent chemo radiotherapy schedule while one used 
a sequential approach (Work). Trials are using a cisplatine based 
chemotherapy and a continuous irradiation (a split-course schedule was 
only used in the Work trial). The timing of chest RT varies from 42 to 
169 days for the late group and during the ﬁrst cycle of chemotherapy 
for the early group. Three trials are in favour of an early administra-
tion (Murray, Skarios, Jeremic) while 3 are in favour of a late chest RT 
(Spiro, Work, Perry). Except for Murray and Works trials, the late chest 
irradiation was delivered within 64 days and certainly not at the end of 
the chemotherapy programme. It is interesting to compare the results 
of Spiro and Murray trial with a very similar design but leading to dif-
ferent results: the Spiro trial favours the late chest RT while the Murray 
is in favour of an early administration. There are some differences in 
the treatment design: the timing of chest radiotherapy was respectively 
on day 22 and 105 for Murray trial and on day 1 and 64 for the Spiro 
trial The radiation schedule was also slightly different: 40 Gy in 15 
fractions over 3 weeks for Murray and 50 Gy in 25 fractions over 5 
weeks for Spiro. Nevertheless, chemotherapy compliance was certainly 
the main difference between the two trials: in Spiro trial, the six cycles 
of chemotherapy were given to 69% of the patients in the early RT vs. 
80% for the late group while in the Murray trial there was no major 
difference between the two arms with a chemotherapy compliance over 
80%. In general, the compliance to chemotherapy was reduced in most 
trials in case of the early chest RT (Skarios, Work, Perry). 
Different metaanalysis have been conducted including some of those 
trials and other trials not especially design to study the timing but were 
a difference in timing was observed between the two arms (An alternat-
ing schedule vs. a sequential for the Gregor trial and an early concur-
rent approach vs. a sequential for the Japanese trial). The deﬁnition of 
early varies from one metaanalysis to another (from within one month 
or before the 3 cycles of chemotherapy). 
In those metaanalysis, there was a trend in favor of an early radiothera-
py when the non-platinum chemotherapy trials were excluded. In Fried 
metaanalysis including 7 trials, an early RT means an RT delivered 
within 9 weeks or before the 3 cycles of chemotherapy. A beneﬁt in 
favor of an early chest RT was seen only for platinum based chemo-
therapy and for hyper fractionated radiation schedule. In the Cochrane 
analysis, only a trend was observed in favor of a chest RT delivered 
within 30 days after the start of chemotherapy after excluding the Perry 
trial. If 5-year data are taking into account, then thoracic radiation de-
livered within 30 days after the start of radiation increases the survival 
from 13.8 to 20.2% but at the expense of more acute toxicity, esophagi-
tis and leucopenia. 
Furthermore, reviewing the data available from randomized trial, De 
Ruysscher and Vansteenkiste introduced the SER concept: this is the 
time elapsed between the start of any therapy and the end of the radia-
tion: in an analysis including 5 trials (Takada, Jeremic, Murray, Work 
and Turrisi), a short SER time let to a clear survival beneﬁt This con-
cept is based on the assumptions that the ﬁrst cytotoxic insult may trig-
gers an accelerated tumor repopulation and a more aggressive treatment 
is an important issue. It is interesting to notice that in Murray trial the 
radiation was an accelerated schedule 45 Gy in 3 weeks and in Turrisi 
trial the accelerated schedule (45 Gy in 3 weeks with 2 fractions a day) 
let to a clear survival advantage over the classical 45 Gy in 5 weeks.
In conclusion, there is certainly not a clear answer but the data may 
suggest a small advantage for a concurrent chemo radiotherapy ap-
proach and an early administration of chest radiotherapy. This implies 
to have an adequate patient selection including the extent of the tumor 
and the patient co morbidities, to avoid an excessive toxicity and to 
ensure a good compliance to the subsequent chemotherapy cycles. This 
raises another question: is the classical deﬁnition of limited disease the 
good one to help us to select the patient for an aggressive approach. 
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For three decades, trials of new chemotherapy regimens for small cell 
lung cancer (SCLC) have failed to substantially improve clinical out-
comes. The promise of targeted therapy has yet to be realised for SCLC 
but there is cautious optimism that there will soon be a breakthrough 
for this disease. 
Angiogenesis Inhibitors : To date the majority of agents evaluated 
in SCLC have been inhibitors of angiogenesis. Trials of interferons 
conducted during the early 1990’s were halted due to lack of signiﬁ-
cant beneﬁt and toxicities that limited administration [1-4]. Trials of 
matrix metalloproteinase inhibitors also failed, and proved toxic due to 
musculoskeletal toxicity [5,6]. The ﬁrst evidence that inhibition of an-
giogenesis may be a viable therapeutic strategy comes from the results 
of a randomised, phase III, placebo-controlled trial of maintenance 
thalidomide in patients with previously untreated extensive stage SCLC 
conducted by the French Intergroup [7]. The thalidomide treated group 
had a median survival of 11.7 months versus 8.7 months for the pla-
cebo group (HR: 0.48 [95% CI: 0.24-0.93]; p = 0.03). However toxic-
